Cooperative Agreement U43AA032128
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $1M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Washington, USA
Similar Awards
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $901,666 Project Grant to Research Triangle Institute (RTI International) to develop small molecule modulators of the RXFP3 receptor as potential therapeutic agents for alcohol use disorder (AUD). The project aims to further optimize and evaluate the effectiveness of the RXFP3 negative allosteric modulators (NAMs) RLX-33 and RLX-79 in animal models of alcohol...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $999,393 Cooperative Agreement to Stress Therapeutics, Inc., a California-based pharmaceutical company, to conduct Investigational New Drug (IND)-enabling studies for a novel therapeutic to treat Alcohol Use Disorder (AUD). The key products and services to be delivered include: 1) Manufacture and validation of the test article for IND-enabling studies; 2) Development and...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $390,454 Project Grant to Envisbio LLC to develop novel therapeutic aptamers targeting phosphodiesterase 4B (PDE4B) for the treatment of alcohol use disorder (AUD). The project aims to identify and characterize PDE4B-specific aptamers that can modulate PDE4B activity, with the goal of advancing these modulators into in vivo testing and eventual human clinical trials for...
- This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...
- This federal Project Grant award of $152,643 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), supports the development and characterization of a novel positron emission tomography (PET) radioligand, (S)-[18F]OF-NB1, to quantify the availability of GluN2B-containing N-methyl-D-aspartate receptors (GluN2BR) in people with alcohol use disorder (AUD). The two-phase project will first establish the imaging properties and...
- This federal Project Grant award of $423,313, provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), aims to develop an AI-driven platform for identifying potential therapeutic candidates for Alcohol Use Disorder (AUD). The award to Biosymetrics Inc., based in Huntington, NY, will leverage the company's existing AI-based zebrafish behavioral screening technology and AUD-specific experimental findings to create a commercial...
- This Project Grant award was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), which falls under the federal Alcohol Research Programs (CFDA 93.273). The $692,723 award will support a double-blind, placebo-controlled clinical trial to test whether the drug suvorexant can be used as a novel therapeutic for alcohol use disorder (AUD) and stress-related drinking. The 5-year project, running from September 2025 through August 2030, will be conducted by researchers at The...
- Under a $368,673 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded on September 25, 2023, Artiam Bio Inc., a minority-owned small disadvantaged biotechnology company, is developing and evaluating second-generation partial inverse agonists targeting the type 1 cannabinoid (CB1) receptor as a potential therapy for alcohol use disorder (AUD). Artiam Bio is conducting preclinical efficacy studies of its lead CB1 receptor partial inverse agonist compound in rat...
- This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) provides $569,223 to examine the efficacy and tolerability of a ketone supplement drink (KS) in reducing alcohol craving and consumption among individuals with alcohol use disorder (AUD). The award period runs from August 1, 2025 to July 31, 2030. The key goals are to determine if KS can improve brain energetics and affect the pharmacokinetic...
- This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) provides $3,168,729 to New York University to conduct a collaborative research project titled "A Translational Approach for Novel Precision Medicine Models." The project aims to identify novel molecular targets and mechanisms of treatment responses in alcohol use disorder (AUD) based on the role of mitochondrial metabolism and epigenetic...